BR0308076A - Irreversibly selective selective androgen receptors and their methods of use - Google Patents
Irreversibly selective selective androgen receptors and their methods of useInfo
- Publication number
- BR0308076A BR0308076A BR0308076-5A BR0308076A BR0308076A BR 0308076 A BR0308076 A BR 0308076A BR 0308076 A BR0308076 A BR 0308076A BR 0308076 A BR0308076 A BR 0308076A
- Authority
- BR
- Brazil
- Prior art keywords
- msra
- compounds
- androgen
- androgen receptor
- cancer
- Prior art date
Links
Abstract
"MODULADORES SELETIVOS RECEPTORES DE ANDROGêNIO IRREVERSìVEIS E SEUS MéTODOS DE USO". Em uma forma de incorporação, esta invenção provê uma nova classe de agentes direcionantes receptores de androgênio (ADRA). Estes agentes que definem uma nova subclasse de compostos, que são moduladores seletivos receptores de androgênio (MSRA) . Os compostos MSRA se unem irreversivelmente ao receptor de androgênio. Em outra forma de incorporação, os compostos MSRA são receptores antagonistas de androgênio que se unem irreversivelmente ao receptor de androgênio. Em outra forma de incorporação, os compostos MSRA são agentes alquilantes. Os compostos MSRA, tanto sozinhos ou em uma composição, servem para a) contracepção masculina; b) tratamento de uma variedade de estados relacionados a hormónios, por exemplo estados associados ao Declínio Androgênico em Envelhecimento Masculino (DAEM) , como fadiga, depressão, diminuição de libido, disfunção sexual, disfunção erétil, hipogonadismo, osteoporose, perda de cabelo, anemia, obesidade, sarcopenia, osteopenia, hiperplasia benigna de próstata, alterações de humor e cognição, e câncer de próstata; c) tratamento de estados associados ao Declínio Androgênico Feminino (DAF), como disfunção sexual, diminuição da libido sexual, hipogonadismo, sarcopenia, osteopenia, osteoporose, alterações de humor e de cognição, depressão, anemia, perda de cabelo, obesidade, endometriose, câncer de mama, câncer uterino e câncer ovariano; d) tratamento e/ou prevenção de estados de degeneração muscular aguda ou crónica; e) prevenção e/ou tratamento de estados de 'olho seco'; f) terapia de reposição androgênica oral; g) diminuição da incidência, interrompendo, ou causando uma regressão de câncer de próstata; e/ou h) induzindo apoptose em uma célula de câncer."IRREVERSIBLE SELECTIVE ANDROGEN RECEPTOR MODULATORS AND THEIR METHODS OF USE". In one embodiment, this invention provides a new class of androgen receptor targeting agents (ADRA). These agents define a new subclass of compounds, which are selective androgen receptor modulators (MSRA). MSRA compounds bind irreversibly to the androgen receptor. In another embodiment, the MSRA compounds are androgen antagonist receptors that irreversibly bind to the androgen receptor. In another embodiment, the MSRA compounds are alkylating agents. The MSRA compounds, either alone or in a composition, serve for a) male contraception; b) treating a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Male Aging (DAEM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia. obesity, sarcopenia, osteopenia, benign prostate hyperplasia, mood and cognitive changes, and prostate cancer; c) treatment of conditions associated with Female Androgen Decline (DAF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, mood and cognition disorders, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and / or prevention of acute or chronic muscle degeneration states; e) prevention and / or treatment of dry eye conditions; f) oral androgen replacement therapy; g) decreased incidence by stopping or causing a regression of prostate cancer; and / or h) inducing apoptosis in a cancer cell.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8467902A | 2002-02-28 | 2002-02-28 | |
US12024802P | 2002-10-23 | 2002-10-23 | |
PCT/US2003/003121 WO2003074473A2 (en) | 2002-02-28 | 2003-02-24 | Irreversible selective androgen receptor modulators and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0308076A true BR0308076A (en) | 2005-08-23 |
Family
ID=34840750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0308076-5A BR0308076A (en) | 2002-02-28 | 2003-02-24 | Irreversibly selective selective androgen receptors and their methods of use |
Country Status (1)
Country | Link |
---|---|
BR (1) | BR0308076A (en) |
-
2003
- 2003-02-24 BR BR0308076-5A patent/BR0308076A/en not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0510822A (en) | selective androgen receptor modulator metabolites and their methods of use | |
BR0307981A (en) | Substituted haloacetamide and azide compounds and their methods of use | |
BR0312172A (en) | Selective nitrogen bridging androgen receptor modulators and their methods of use | |
BR0308176A (en) | Selective multi-substituted androgen receptor modulators and their methods of use | |
TW200420571A (en) | Halogenated selective androgen receptor modulators and methods of use thereof | |
TW200503711A (en) | Methylene-bridged selective androgen receptor modulators and methods of use thereof | |
EP1487458A4 (en) | Multi-substitued selective androgen receptor modulators and methods of use thereof | |
WO2004035737A3 (en) | Heterocyclic selective androgen receptor modulators and methods of use thereof | |
WO2003074473A3 (en) | Irreversible selective androgen receptor modulators and methods of use thereof | |
EA200400337A1 (en) | APPLICATION OF THE GLUCOCORTICOID RECEPTOR MODULATOR AND THE GLUCOCORTICOID RECEPTOR AGONIST WHEN RECEIVING A MEDICINE | |
MX2009000715A (en) | Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof. | |
MX2016001969A (en) | Methods of treating sporadic inclusion body myositis. | |
AR052774A1 (en) | IMMUNOTHERAPY FOR AUTOIMMUNE DISORDERS | |
EA201100133A1 (en) | ANTAGONISTS OF PROSTAGLANDIN RECEPTORS D | |
EP1606264A4 (en) | Monocyclic anilide spirohydantoin cgrp receptor antagonists | |
CL2008002744A1 (en) | Compounds derived from 1,3-disubstituted-4-phenyl-1h-pyridin-2-one, allosteric modulators of the glutamatergic receptor mglur2; Pharmaceutical composition and use of the compounds in the treatment of neurological and psychiatric conditions mediated by mglur2. | |
BR0313624A (en) | 5ht2a receptor agonism for treatment of thermoregulatory dysfunction | |
MX2017010544A (en) | Methods and compositions for treating dry eye disease and other eye disorders. | |
EA201070725A1 (en) | BIS-Pyridylpyridones as antagonists of receptor 1 melaninconcentrating hormone | |
TW201713341A (en) | Compositions and methods of treating a neurodegenerative disease | |
MX2023008760A (en) | Combination therapy of lasmiditan and a cgrp antagonist for use in the treatment of migraine. | |
MX2023000677A (en) | Estrogen receptor-modulating compounds. | |
MX2020008680A (en) | Combination therapy with apilimod and glutamatergic agents. | |
MX2007003545A (en) | Compositions and methods for treating cognitive disorders. | |
PH12019500326A1 (en) | Combination of fxr agonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired |